Silexion Therapeutics Files 8-K

Ticker: SLXN · Form: 8-K · Filed: Apr 28, 2026 · CIK: 0002022416

Silexion Therapeutics Corp 8-K Filing Summary
FieldDetail
CompanySilexion Therapeutics Corp (SLXN)
Form Type8-K
Filed DateApr 28, 2026
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, regulatory-filing

TL;DR

Silexion Therapeutics filed an 8-K on 4/28/26 with new disclosures and exhibits.

AI Summary

Silexion Therapeutics Corp. filed an 8-K on April 28, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing includes an iXBRL 8-K document, an exhibit (EX-99.1), and various XBRL taxonomy extension files. The company's mailing and business address is in Ramat Gan, Israel.

Why It Matters

This 8-K filing indicates that Silexion Therapeutics Corp. is providing updated information or disclosures to the public, which could be material for investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not appear to contain any immediately alarming or negative information.

Key Numbers

  • 0002022416 — CIK Number (Identifies Silexion Therapeutics Corp in SEC filings.)
  • 2026-04-28 — Filing Date (Date Silexion Therapeutics Corp submitted this 8-K report.)

Key Players & Entities

  • Silexion Therapeutics Corp (company) — Filer of the 8-K
  • 0002022416 (company) — CIK number for Silexion Therapeutics Corp
  • 2026-04-28 (date) — Filing date and period of report

FAQ

What specific information is disclosed under Regulation FD?

The filing indicates a Regulation FD Disclosure under Item 7.01, but the specific content of this disclosure is contained within Exhibit 99.1 and the main 8-K document, which would require further examination.

What type of financial statements or exhibits are included?

Item 9.01 mentions Financial Statements and Exhibits, with Exhibit 99.1 listed as a key document, along with various XBRL files.

Where is Silexion Therapeutics Corp. located?

The company's mailing and business address is listed as 12 ABBA HILLEL ROAD, RAMAT GAN L3 5250606, Israel.

What is the SIC code for Silexion Therapeutics Corp?

The SIC code is 2836, which pertains to Biological Products, (No Diagnostic Substances).

What is the purpose of the XBRL taxonomy extension files?

These files (SCHEMA, DEFINITION, LABEL, PRESENTATION) are used to extend the standard XBRL taxonomy, allowing for more specific and detailed financial reporting by Silexion Therapeutics Corp.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 28, 2026 regarding Silexion Therapeutics Corp (SLXN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.